Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
09/2005
09/22/2005WO2005087727A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005WO2005087713A1 Amide compound, pharmaceutical composition and rxr function control agent
09/22/2005WO2005087268A1 Axon regeneration promoter
09/22/2005WO2005087252A1 Use of dm43 and its fragments as matrix metalloproteinases inhibitor
09/22/2005WO2005087237A1 Fasudil-containing preparation and method of improving stability thereof
09/22/2005WO2005087219A1 Memory fixation accelerator
09/22/2005WO2005087213A1 Combination of deramciclane and opoids as analgesics
09/22/2005WO2005087212A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
09/22/2005WO2005087022A1 Food composition having antistress effect
09/22/2005WO2005044093A3 Delta-9- the treatment of multiple sclerosis
09/22/2005WO2005003104A3 Crystalline forms of lamotrigine monohydrate and anhydrous lamotrigine and a process for their preparation
09/22/2005WO2004060265A3 Eye-drop vaccine containing copolymer 1 for therapeutic immunization
09/22/2005WO2000075279A3 Nucleotide sequences for gene regulation and methods of use thereof
09/22/2005US20050210538 Screening for a developmental promoter or a developmental suppressor of oligodendrocytes, or a promoter or a suppressor of myelinogenesis, diagnostic for neuropsychiatric disorders
09/22/2005US20050209341 R-(-)-N-methyl 3-((2-methyl-4-hydroxyphenyl)oxy)-3-phenyl-1-aminopropane or its hydrochloride salt; inhibiting the uptake of norepinephrine and serotonin; antidepressants, analgesics; treating sleep disorders, autism, psychological disorders, eating disorders
09/22/2005US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases
09/22/2005US20050209329 Potentiation of therapeutic effects of fatty acids
09/22/2005US20050209316 Lactone formulations and method of use
09/22/2005US20050209302 Glycogen synthase kinase (GSK-3) inhibitors; diabetes, neurodegenerative diseases, stroke, neurotraumatic injuries and bipolar disorders; 5-acetyl-3-[3-(methoxycarbonylpropylamino)-(benzo-[1.3]dioxyo-5-yl)-methylidene]-2-indolinone for example
09/22/2005US20050209281 Salt formation by dissolving donepezil in ethanol, adding hydrogen chloride, forming polymorphic crystal; simplification; safety to environment and the bodies of operators; and can produce at low costs
09/22/2005US20050209273 Neuroprotectants, analgesics or anticonvulsants
09/22/2005US20050209267 Thioether substituted imidazoquinolines
09/22/2005US20050209261 Rho-kinase inhibitors
09/22/2005US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol
09/22/2005US20050209241 Benzoyl-piperazine derivatives
09/22/2005US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors
09/22/2005US20050209236 For therapy or prophylaxis of diseases and for improving perception, concentration, learning and/or memory
09/22/2005US20050209233 Neuropeptide Y5 (NPY-5) receptor antagonists or agonists; eating disorders, diabetes dyslipidemia, hypertension, and sleep disorders; pyridazin-3-ylamino-substituted dibenzothiophenes and S-oxides thereof
09/22/2005US20050209228 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
09/22/2005US20050209225 Substituted indoles and their use as integrin antagonists
09/22/2005US20050209222 Pharmaceutically active compounds and methods of use
09/22/2005US20050209217 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors
09/22/2005US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline
09/22/2005US20050209213 Quinoline compound
09/22/2005US20050209192 Autoimmune disorders; modulating protein kinase C activity
09/22/2005US20050209169 Respiratory disorders such as pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis
09/22/2005US20050209140 Methods of controlling axonal growth
09/22/2005US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist
09/22/2005US20050208619 29 human secreted proteins
09/22/2005US20050208582 Pyrazole compounds and pharmaceutical compositions comprising the compound
09/22/2005US20050208525 Nucleotide sequences coding preferential polypeptide for use in the treatment defects in immune and inflammatory response
09/22/2005US20050208484 Isolated nucleic acid molecules encoding human drugmetobolizing proteins
09/22/2005US20050208156 Plants extracts and the use thereof
09/22/2005US20050208154 Antidepressants for treating manic disorders, psychosis; comprising ethyl cellulose, talc, polyvinylpyrrolidone; time-release dosage form; once daily
09/22/2005US20050208135 Monocompartment osmotic controlled drug delivery system
09/22/2005US20050208129 Prolonged release bioadhesive therapeutic systems
09/22/2005US20050208126 Chemical ifg-i composition for the treatment and prevention of neurodgenerative diseases
09/22/2005US20050208125 Substantially pure solid form of the enol tautomer of 3-indolypyruvic acid for use in the treatmetn of central nervous system disturbances
09/22/2005US20050208050 Compounds for the diagnosis/prevention/treatment of alzheimer's disease
09/22/2005US20050208044 Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof
09/22/2005US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin
09/22/2005US20050208001 rosacea, intrinsic or chronological aging, pigmentation, seborrhoeic function, barrier function, epidermal lipid secretion, wound healing, atrophies, ulcers, immune system, cardiovascular system disorders; 6-(5,6,7,8-tetrahydro-5,5,8,8-tetra-methylnaphthalene-2-carbonyl)naphthalene-2-carboxylic acid
09/22/2005DE102004010254A1 New 4-heterocyclyl-1-acyl-piperidine derivatives, useful e.g. for treating headache, diabetes and cardiovascular disease, are antagonists of calcitonin-gene related peptide
09/22/2005DE10152351B4 Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat Solid pharmaceutical formulation for a Piperazinharnstoffderivat
09/22/2005CA2560098A1 2-aminoquinazoline derivative
09/22/2005CA2559802A1 Method for stimulating the immune, inflammatory or neuroprotective response
09/22/2005CA2559493A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
09/22/2005CA2559487A1 Combination of deramciclane and opoids as analgesics
09/22/2005CA2559139A1 Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
09/22/2005CA2559069A1 Axon regeneration promoter
09/22/2005CA2558899A1 Fused ring azadecalin glucocorticoid receptor modulators
09/22/2005CA2558249A1 Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
09/22/2005CA2558036A1 Substituted hydroxyethylamine aspartyl protease inhibitors
09/22/2005CA2556826A1 Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
09/21/2005EP1577323A1 Metastin derivative and use thereof
09/21/2005EP1577311A1 Salts of a pyridazino aquinoline derivative and use for the treatment of pain
09/21/2005EP1577296A1 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their use
09/21/2005EP1577295A1 Process for preparing 2-oxo-1-pyrrolidine derivatives as intermediates
09/21/2005EP1577294A1 S-substituted n-1- (hetero)aryl alkyl-n - (hetero)aryl alkylysothiocarbamides, method for the production thereof, physiologically active s-substituted n-1- (hetero )aryl alkyl-n - (hetero)aryl alkylysothiocarbamides,a pharmaceutical compound and curing method
09/21/2005EP1577288A1 Selective estrogen receptor modulators
09/21/2005EP1576986A2 Sustained-release tramadol formulations with 24-hour clinical efficacy
09/21/2005EP1576985A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
09/21/2005EP1576964A1 Protease inhibitor
09/21/2005EP1576963A2 Method for treating pain by peripheral administration of a neurotoxin
09/21/2005EP1576958A1 An composition containing triterpenoid saponins extracted from bamboo, and the preparation method and use thereof
09/21/2005EP1576955A1 Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR) 1,3a,8 trimethyl 1,2,3,3a,8,8a hexahydropyrrolo[2,3 b]indol 5 yl phenylcarbamate
09/21/2005EP1576954A1 Preferential inhibition of release of pro-inflammatory cytokines
09/21/2005EP1576953A1 Propofol-containing fat emulsions
09/21/2005EP1576168A2 Therapeutic polypeptides nucleic acids encoding same and methods of use
09/21/2005EP1576118A2 ALLELE-SPECIFIC siRNA-MEDIATED GENE SILENCING
09/21/2005EP1576088A2 Dominant negative proteins and methods thereof
09/21/2005EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
09/21/2005EP1575984A2 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
09/21/2005EP1575962A1 Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
09/21/2005EP1575960A2 1,4-diazabicyclo 3.2.2]nonanecarboxamide derivatives, preparation and therapeutic use thereof
09/21/2005EP1575954A2 Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
09/21/2005EP1575942A1 Novel compounds having selective inhibiting efect at gsk3
09/21/2005EP1575939A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575938A1 Novel compounds having selective inhibiting effect at gsk3
09/21/2005EP1575918A2 Substituted biaryl-4-carboxylic acid arylamide analogues as capsaicin receptor modulators
09/21/2005EP1575916A2 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
09/21/2005EP1575915A1 Modafinil polymorphic forms
09/21/2005EP1575658A2 Screening and therapeutic methods for treating circadian rhythm disorders
09/21/2005EP1575607A1 Vanilloid receptor-2 ligands for treating anxiety or depression
09/21/2005EP1575594A2 Combination of reboxetine and a cyclooxygenase-2 inhibitor
09/21/2005EP1575590A1 Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
09/21/2005EP1575586A1 2-pyridyl and 2-pyrimidyl cycloalkylene amide compounds as nr2b receptor antagonists
09/21/2005EP1575585A1 Pharmaceutical liquid composition containing pyridone derivative
09/21/2005EP1575578A2 Methods of treating injuries of the nervous system associated with hemorrhage
09/21/2005EP1575576A2 Organic compounds
1 ... 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 ... 1833